GlassScriptPhysician profile
Audra M Malerba
NPI 1578682985
$8,989.52
in general payments reported to CMS, 2019-2025
34 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $1,313 · 2021: $1,546 · 2022: $889 · 2023: $1,052 · 2024: $2,348 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,180 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,180.05 |
| Education | $137.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $2,075.15 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,270.57 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $745.16 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $741.10 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $493.08 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $492.20 | 2019-2025 | Cabtreo, Jublia |
| Novartis Pharmaceuticals Corporation | $376.99 | 2019-2025 | |
| Pfizer INC. | $342.26 | 2020-2025 | |
| Genzyme Corporation | $314.62 | 2019-2023 | |
| Amgen INC. | $292.94 | 2021-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $216.38 | 2019-2024 | |
| Dermavant Sciences, INC. | $147.84 | 2023-2024 | Vtama |
| Dermira, INC. | $138.96 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $136.60 | 2019-2021 | |
| Lilly USA, LLC | $132.73 | 2019-2025 | Ebglyss, Taltz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $132.61 | 2019-2023 | Epsolay |
| Almirall LLC | $119.73 | 2020-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $110.20 | 2022-2024 | Sotyktu |
| Epi Health, LLC | $97.44 | 2019-2021 | |
| Biofrontera INC. | $96.72 | 2019-2021 | |
| Revance Therapeutics, INC. | $72.51 | 2024 | Daxxify |
| Sandoz INC. | $65.73 | 2019-2020 | |
| Ucb, INC. | $59.74 | 2021-2024 | Cimzia, Bimzelx |
| Journey Medical Corporation | $46.51 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $44.79 | 2019-2020 | |
| Mission Pharmacal Company | $39.95 | 2020-2021 | |
| Strata Skin Sciences, INC. | $36.70 | 2020-2024 | Xtrac |
| Incyte Corporation | $33.62 | 2021-2025 | Opzelura |
| Celgene Corporation | $24.02 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.67 | 2023 | Ycanth |
| Botanix Sb INC | $21.74 | 2025 | Sofdra |
| Organon LLC | $18.61 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $16.98 | 2019 | |
| Encore Dermatology INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Malerba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.